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closely related to a genotypic group of
viruses isolated from the eastern
United States and two Caribbean
countries from 1999 to 2001 (6).
Results from our phylogenetic analy-
sis showed that Thess1/GRE99, as
well as strains G432/GER99 and
6423/PV/ITA97 (and the United
Kingdom 1999 strains), were cluster-
ing with strains FRI/BAH97 (acces-
sion no. AY326359), isolated in 1997
from the Bahamas, and DES/MB-
CAN97 (AY326358), isolated in 1997
from Manitoba, Canada (which also
belong to the international 1997–2000
RGI genotype). These findings indi-
cated that this rubella strain was circu-
lating in both Europe and North
America at least as early as 1997. 
Recent data indicate that interna-
tionally circulating rubella viruses
exist, even when vaccination pro-
grams are conducted. Comprehensive
specimen collection and genotypic
analysis are necessary to identify and
track the emergence and spread of
such genotypes.
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CTX-M 
β-Lactamase–
producing
Escherichia coli in
Long-term Care
Facilities, France 
To the Editor: In long-term care
facilities, most endemic infections
affect respiratory and urinary tracts,
as well as skin and soft tissues (1–3).
Infection and colonization by antimi-
crobial-resistant organisms, in partic-
ular those producing plasmid-mediat-
ed extended-spectrum β-lactamases
(ESBL), are common in long-term
care facilities (4). Since 1984, ESBL-
producing Enterobacteriaceae have
spread among French hospitals; with-
in Parisian public hospitals
(Assistance Publique, Hôpitaux de
Paris), ESBL-producing Escherichia
coli is the most frequent species
found, representing 49.5% of 220
Enterobacteriaceae isolated in 2002,
mostly in urinary tract infections (5).
Among ESBL-producing Entero-
bacteriaceae, CTX-M–type β-lacta-
mases confer a higher level of resist-
ance to cefotaxime and ceftriaxone
than to ceftazidime. CTX-M–produc-
ing strains are endemic in Latin
America, Japan, and certain parts of
Eastern Europe; in contrast, these
strains are emerging in France,
Western Europe, and the United States
(6). We report the first documented
outbreak of CTX-M–producing E.
coli infection in a long-term care
facility in France. Our hospital is an
800-bed institution with 300 beds for
long-term patients distributed among
three units located in two buildings.
The outbreak occurred in a 35-bed
unit and involved 26 of 47 hospital-
ized patients from October 2001 to
March 2003. This facility hosts
patients for extended periods of time
or permanently. The index case was
identified in October 2001; the patient
had a urinary tract infection attributa-
ble to an ESBL-producing E. coli,
which showed resistance patterns not
previously found in our hospital.
Three new cases were detected within
the following 2 months, and all
patients had urinary tract infection
with the same pattern of resistance. In
January 2002, patients were screened
for ESBL-producing strains by rectal
swabbing and urine culture. The
results showed E. coli with a high
level of resistance to amoxicillin and
ticarcillin (MIC > 128 µg/mL), partial
restoration of susceptibility to these
agents by addition of clavulanic acid
(MIC = 16–32 µg/mL), and higher
resistance to cefotaxime (MIC > 128
µg/mL) than to ceftazidime (MIC =
32–64 µg/mL.) A cephalosporin/co-
amoxiclav synergy test was positive,
which suggests a CTX-M ESBL.
Strains were also resistant to
ciprofloxacin (MIC 64 µg/mL) and
gentamicin (MIC > 64 µg/mL) but
remained susceptible to trimethoprim-
sulfamethoxazole. 
Attempts to transfer resistance to
β-lactams by conjugation to E. coli
J53-2 with the 26 strains tested were
unsuccessful. In contrast, transfor-
mants were obtained with plasmid
DNA of the 19 strains tested by elec-
troporation. The transformants’ sus-
ceptibility pattern was similar to that
of the donor strains, except for
ciprofloxacin resistance. Analytical
isoelectric focusing showed that all
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clinical strains and transformants had
bands of β-lactamase activity with an
alkaline pI of 7.6 and 5.4. Polymerase
chain reaction (PCR) amplification of
the 26 clinical isolates was positive
for blaCTX-M and blaTEM (7). The 26
strains of E. coli had the same profile
by repetitive-element PCR and
pulsed-field gel electrophoresis, while
unrelated control strains had very dif-
ferent profiles. Sequencing in strains
isolated from four of the patients iden-
tified a CTX-M-15 β-lactamase and a
TEM-1 β-lactamase. The four strains
were related to the phylogenetic
group B2 and produced the iutA (fer-
ric aerobactin receptor), YuA
(Yersinia siderophore receptor), and
fimH (type I fimbriae) virulence fac-
tors (8). Incidence of colonization or
infection by the culprit strain was
34.3% (12 of 35 patients) within the
initial 4-month period and 55.3% (26
of 47 patients) over a 1-year period.
Intensified hygienic procedures
implemented in January 2002 con-
tributed to a decrease in the number of
cases in February only; since then, a
regular increase of new cases extend-
ed the outbreak and caused problems
with controlling it. All urinary tract
infections were successfully treated
with a 15-day course of trimethoprim-
sulfamethoxazole; however, reinfec-
tion occurred in some. Neither incon-
tinence (p = 0.35), dementia (p =
0.22), nor previous antibiotic treat-
ment (amoxicillin, amoxicillin-clavu-
lanic acid, extended-spectrum
cephalosporins, and fluoroquinolones
[p = 1.00, 0.30, 0.12, 0.52, respective-
ly]) appeared to be risk factors for
infection or colonization in our study,
but the number of patients is too small
to reach a conclusion. However,
patients that were infected or colo-
nized had greater functional impair-
ment, especially incontinence and
dementia. Nonambulatory status,
decubitus ulcers, and feeding tubes
were not risk factors for acquiring
ESBL-producing E. coli in our study.
The outbreak has not been con-
trolled: 13 patients have persistent
digestive-tract colonization. Diffi-
culties encountered in controlling
such outbreaks may be explained by
several factors. Patients cannot be
easily isolated in long-term care facil-
ities. Strict isolation and limitation of
activity and mobility cannot always
be applied because of their impact on
social activities.
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Do Antiborrelial
Antibodies Suggest
Lyme Disease in
Cuba? 
To the Editor: Lyme disease is the
most common vector-borne disease in
the United States and parts of Eurasia
(1). It represents a considerable
emerging infectious disease threat
because of its consequences to human
health and the difficulties in prevent-
ing and controlling it (2,3).
In Cuba, Lyme borreliosis has
never been reported. However, in the
last 20 years ixodid ticks, mainly
Amblyomma cajennenses, have been
found in the human population in the
Cuban village of Las Terrazas, Pinar
del Río. These ixodid bites were fre-
quent and widespread, especially in
children, many of whom were hospi-
talized without a confirmatory labora-
tory diagnosis. Affected persons had
symptoms associated with Lyme dis-
ease such as erythematous macules or
papules, fever, fatigue, malaise,
headache, arthralgias, myalgias,
meningitis, peripheral radiculoneu-
ropathies, and myocarditis (4). 
A Cuban researcher, a specialist in
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